IPSEN (OTCMKTS:IPSEY) Stock Short Interest Falls 57.5%

IPSEN (OTCMKTS:IPSEY – Get Free Report) saw a large drop in short interest in October. As of October 15th, there was short interest totaling 606 shares, a drop of 57.5% from the September 30th total of 1,426 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 5,390 shares, the short-interest ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on IPSEY shares. Barclays raised shares of IPSEN from a “strong sell” rating to a “hold” rating in a report on Thursday, September 17th. Jefferies Financial Group cut shares of IPSEN from a “hold” rating to a “moderate sell” rating in a research report on Sunday, August 2nd. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold”.

Check Out Our Latest Stock Analysis on IPSEY

IPSEN Price Performance

IPSEY opened at $44.35 on Friday. IPSEN has a 52-week low of $34.34 and a 52-week high of $51.10. The stock’s 50 day moving average price is $44.02 and its 200-day moving average price is $45.16.

About IPSEN

(Get Free Report)

Ipsen SA is a France-based biopharmaceutical company focused on developing and commercializing medicines for serious diseases. Its principal therapeutic areas are oncology, rare diseases and neuroscience, with operations spanning research, clinical development, manufacturing and commercial activities.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and rare endocrine conditions, Dysport (abobotulinumtoxinA) for therapeutic and aesthetic uses, and Onivyde (a liposomal formulation of irinotecan) for pancreatic cancer.

See Also

Receive News & Ratings for IPSEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN and related companies with MarketBeat.com's FREE daily email newsletter.